
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNTHROID | AbbVie | N-021402 RX | 2002-07-24 | 12 products, RLD |
| THYRO-TABS | Alvogen | N-021116 RX | 2002-10-24 | 12 products, RLD |
| LEVO-T | Cediprof | N-021342 RX | 2002-03-01 | 12 products |
| LEVOTHYROXINE SODIUM | Fresenius Kabi | N-202231 RX | 2011-06-24 | 3 products, RLD, RS |
| LEVOTHYROXINE SODIUM | Fresenius Kabi | N-210632 RX | 2019-04-11 | 3 products, RLD, RS |
| LEVOLET | Genus Lifesciences | N-021137 RX | 2003-06-06 | 12 products |
| LEVOTHYROXINE SODIUM | Hikma Pharmaceuticals | N-214253 RX | 2021-05-17 | 1 products, RLD, RS |
| TIROSINT | IBSA Group | N-021924 RX | 2006-10-13 | 15 products, RLD |
| TIROSINT-SOL | IBSA Group | N-206977 RX | 2016-12-15 | 15 products, RLD, RS |
| LEVOXYL | King Pharmaceuticals | N-021301 RX | 2001-05-25 | 11 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| euthyrox | New Drug Application | 2026-01-27 |
| evexithroid | unapproved drug other | 2025-10-12 |
| levothroid | New Drug Application | 2012-03-02 |
| levothyroxine | ANDA | 2026-05-15 |
| levothyroxine sodium | ANDA | 2026-08-12 |
| levoxyl | New Drug Application | 2020-12-15 |
| np thyroid | unapproved drug other | 2021-05-11 |
| np thyroid 120 | unapproved drug other | 2025-12-09 |
| np thyroid 120 np thyroid 15 np thyroid 30 np thyroid 60 np thyroid 90 | unapproved drug other | 2026-01-27 |
| np thyroid 15 | unapproved drug other | 2026-01-20 |
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Levothyroxine Sodium, Tirosint-Sol, Ibsa | |||
| 11241382 | 2039-09-17 | U-3757, U-3758 | |
| 10537538 | 2037-02-28 | DP | |
| 11096913 | 2037-02-28 | DP | |
| Levothyroxine Sodium, Levolet, Genus Lifesciences | |||
| 10231931 | 2038-03-23 | DP | |
| 10406108 | 2038-03-23 | DP | |
| Levothyroxine Sodium, Levothyroxine Sodium, Fresenius Kabi Usa | |||
| 9782376 | 2036-12-01 | DP | |
| 10398669 | 2036-12-01 | DP | |
| 11135190 | 2036-12-01 | DP | |
| 9006289 | 2032-10-03 | DP | |
| 9168238 | 2032-08-29 | DP | |
| 9168239 | 2032-08-29 | DP | |
| Levothyroxine Sodium, Levothyroxine Sodium, Hikma | |||
| 11154498 | 2036-07-20 | DP | |
| Levothyroxine Sodium, Ermeza, Mylan | |||
| 9345772 | 2035-02-27 | DP | |
| Levothyroxine Sodium, Thyquidity, Azurity | |||
| 9050307 | 2031-08-06 | DP | |
| Levothyroxine Sodium, Tirosint, Ibsa | |||
| 7691411 | 2024-03-14 | DP | |
| 7723390 | 2024-03-14 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | 5 | 19 | 12 | 32 | 69 | 129 |
| Thyroid diseases | D013959 | — | E00-E07 | 1 | 10 | 7 | 4 | 33 | 52 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 3 | 7 | 3 | 2 | 18 | 32 |
| Healthy volunteers/patients | — | — | — | 17 | 1 | — | 2 | 1 | 20 |
| Depression | D003863 | — | F33.9 | — | — | 1 | 5 | 4 | 10 |
| Euthyroid sick syndromes | D005067 | EFO_1000931 | E07.81 | 1 | 3 | 1 | 1 | 5 | 10 |
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | 1 | 3 | 3 | 4 | 10 |
| Congenital hypothyroidism | D003409 | — | E00.1 | — | — | — | 3 | 7 | 10 |
| Heart failure | D006333 | EFO_0003144 | I50 | 3 | 2 | 1 | 4 | 1 | 9 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | 3 | 2 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 1 | 1 | — | 5 | 7 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | 4 | 5 |
| Dyslipidemias | D050171 | — | — | — | — | 2 | — | 3 | 5 |
| Neoplasms | D009369 | — | C80 | — | 1 | 1 | — | 3 | 4 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | 3 | 4 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | 2 | — | 2 | 4 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 1 | — | 3 | 4 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | 3 | — | — | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | — | 2 | 3 |
| Congenital heart defects | D006330 | — | Q24.9 | — | — | 2 | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune thyroiditis | D013967 | EFO_0006812 | E06.3 | — | 1 | — | — | 8 | 9 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | — | 1 | 4 |
| Infertility | D007246 | EFO_0000545 | — | — | 1 | — | — | 2 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 2 | 3 |
| Medulloblastoma | D008527 | — | — | 1 | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | — | — | 2 |
| Ependymoma | D004806 | — | — | — | 1 | — | — | — | 1 |
| Alveolar soft part sarcoma | D018234 | — | — | — | 1 | — | — | — | 1 |
| Glucose metabolism disorders | D044882 | — | — | — | 1 | — | — | — | 1 |
| Environmental biomarkers | D000074062 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperthyroidism | D006980 | — | E05.9 | 1 | — | — | — | 6 | 7 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | 1 | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | — | — | — | 1 | 2 |
| Melanosis | D008548 | EFO_0003963 | L81.1 | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 2 | — | — | — | — | 2 |
| Sclerosis | D012598 | — | — | 2 | — | — | — | — | 2 |
| Follicular adenocarcinoma | D018263 | — | — | 1 | — | — | — | — | 1 |
| Analgesia | D000698 | — | — | 1 | — | — | — | — | 1 |
| Anesthesia | D000758 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | — | — | — | 11 | 11 |
| Thyroiditis | D013966 | — | E06 | — | — | — | — | 10 | 10 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 4 | 4 |
| Carcinoma | D002277 | — | C80.0 | — | — | — | — | 3 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 3 | 3 |
| Thyroidectomy | D013965 | — | — | — | — | — | — | 3 | 3 |
| Hyperprolactinemia | D006966 | — | E22.1 | — | — | — | — | 2 | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | — | 2 | 2 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 2 | 2 |
| Thyroid function tests | D013960 | — | — | — | — | — | — | 2 | 2 |
| Drug common name | Levothyroxine |
| INN | levothyroxine sodium |
| Description | L-thyroxine is the L-enantiomer of thyroxine. It has a role as a thyroid hormone, an antithyroid drug, a human metabolite and a mouse metabolite. It is a thyroxine, an iodophenol, a 2-halophenol, a L-phenylalanine derivative and a non-proteinogenic L-alpha-amino acid. It is a conjugate acid of a L-thyroxine(1-). It is an enantiomer of a D-thyroxine. It is a tautomer of a L-thyroxine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O |
| PDB | — |
| CAS-ID | 51-48-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1624 |
| ChEBI ID | 18332 |
| PubChem CID | 5819 |
| DrugBank | DB00451 |
| UNII ID | 054I36CPMN (ChemIDplus, GSRS) |










